JPS60105620A - 尿アルカリ化剤組成物 - Google Patents
尿アルカリ化剤組成物Info
- Publication number
- JPS60105620A JPS60105620A JP21478583A JP21478583A JPS60105620A JP S60105620 A JPS60105620 A JP S60105620A JP 21478583 A JP21478583 A JP 21478583A JP 21478583 A JP21478583 A JP 21478583A JP S60105620 A JPS60105620 A JP S60105620A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- urine
- citric acid
- sodium citrate
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 210000002700 urine Anatomy 0.000 title claims abstract description 44
- 230000003113 alkalizing effect Effects 0.000 title claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000001509 sodium citrate Substances 0.000 claims abstract description 29
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 29
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract description 28
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims abstract description 26
- 235000019797 dipotassium phosphate Nutrition 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 239000011734 sodium Substances 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 230000003355 alkalizing urine Effects 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 4
- 239000001508 potassium citrate Substances 0.000 description 4
- 229960002635 potassium citrate Drugs 0.000 description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 4
- 235000011082 potassium citrates Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- -1 sodium citrate potassium hydrogen diphosphate Chemical compound 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21478583A JPS60105620A (ja) | 1983-11-15 | 1983-11-15 | 尿アルカリ化剤組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21478583A JPS60105620A (ja) | 1983-11-15 | 1983-11-15 | 尿アルカリ化剤組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60105620A true JPS60105620A (ja) | 1985-06-11 |
| JPH0430374B2 JPH0430374B2 (cs) | 1992-05-21 |
Family
ID=16661492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21478583A Granted JPS60105620A (ja) | 1983-11-15 | 1983-11-15 | 尿アルカリ化剤組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60105620A (cs) |
-
1983
- 1983-11-15 JP JP21478583A patent/JPS60105620A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0430374B2 (cs) | 1992-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0535130B2 (cs) | ||
| JP3038456B2 (ja) | ジデオキシプリンヌクレオシドの改良された経口投与処方物 | |
| US3865935A (en) | Tableting of erythromycin base | |
| JP4395338B2 (ja) | 抗生物質活性を有する薬学的組成物 | |
| AU602899B2 (en) | Treatment of hypertension, compounds and compositions for antihypertension and diuresis | |
| US20100227006A1 (en) | Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis | |
| Umeki et al. | Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity | |
| Orme et al. | The effects of long term administration of dopamine on renal function in hypertensive patients | |
| Pearson et al. | The Pathophysiology of Congential Chloridorrhoea | |
| EP0022429B1 (en) | Process for the preparation of gastric acid neutralizing agents and gastric acid neutralizing agents | |
| BG60901B1 (bg) | Гранулат,съдържащ натриев 2-меркаптоетансулфонаткато активно вещество и метод за получаването му | |
| JPS60105620A (ja) | 尿アルカリ化剤組成物 | |
| JPS60197624A (ja) | 尿アルカリ化性食品組成物 | |
| US4098883A (en) | Aluminum compound and pharmaceutical compositions containing same | |
| WO2022042450A1 (zh) | 三羟甲基氨基甲烷药学可接受的盐在治疗高尿酸血症药物中的应用 | |
| EP0443028B1 (en) | Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer | |
| JPS60105619A (ja) | 尿アルカリ化性食品組成物 | |
| JPS60197623A (ja) | 尿アルカリ化剤組成物 | |
| US5430037A (en) | Oxypurinol alkali and alkalane earth salts in amorphous or crystalline form as agents for treating hyperuricaemia and gout | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| Friedman | Observations concerning the effects of (1) sodium salicylate and (2) sodium salicylate and glycine upon the production and excretion of uric acid and allantoin in the rat | |
| JP2772717B2 (ja) | 高尿酸血症および痛風治療用の薬剤としてのアモルファス状または結晶状のオキシプリノールのアルカリ塩およびアルカリ土類塩 | |
| US4271150A (en) | Urokinase preparation for oral administration | |
| JPS59144741A (ja) | ホパンテン酸カルシウム組成物 | |
| Sloan et al. | The effect of chlorpropamide hyponatremia on mental status in a nursing home population |